|
|
|
|
|
|
|
| |
| Timetable |
 |
|
|
To view the full session, please click on the session number |
|
|
Thursday, October 18, 2012 |
|
Hall A |
|
|
|
| 16:00-17:30 |
Pipeline Showcase: New Drugs on the Horizon |
| 17:30-18:00 |
Coffee Break and Poster Exhibition |
|
18:00-19:15 |
SATELLITE SYMPOSIUM
JANSSEN PHARMECUTICALS
DAAs: Raising standards in patient care |
|
19:15-20:30 |
Welcome Reception - Sponsored by Abbott |
|
|
Friday, October 19, 2012 |
|
Hall A |
Hall B |
|
09:00-11:00 |
Plenary Session 2
HCV Direct Acting Antivirals: How have the treatment paradigms changed |
|
11:00-11:30 |
Coffee Break |
|
11:30-12:15 |
Session 3
Do we need to know genetic factors such as IL28B for treatment decision making? |
Session 4
HCV therapy is for specialists only? |
|
12:15-13:00 |
Lunch Break |
|
13:00-14:15 |
SATELLITE SYMPOSIUM
MERCK SHARP & DOHME
Successful HCV Treatment in the Real World: Lessons From Clinical Practice |
|
14:15-15:45 |
|
|
15:45-16:15 |
Coffee Break and Poster Prize Ceremony |
|
16:15-17:00 |
Session 6
Should patients wait for DAA combination therapy? |
Session 7
Resistance to HCV Protease Inhibitors: Game over? |
|
17:00-17:30 |
Session 8
Interactive Case Session: How to treat HCV relapse after Liver Transplant? |
Session 9
Interactive Case Session: How to treat HCV in HIV coinfection
Supported by an unrestricted grant from Boehringer Ingelheim |
|
|
Saturday, October 20, 2012 |
|
Hall A |
|
|
|
| 10:30-11:00 |
Coffee Break |
|
11:00-11:45 |
Plenary Session 11
Interactive Case Session and Discussion: The challenging hepatitis B Case
Supported by an unrestricted grant from Gilead Sciences Europe Ltd |
|
11:45-12:45 |
|
|
12:45-13:00 |
Farewell Toast |
|
|
|
|
|
|
|
WebStudio.co.il